The goal of this clinical trial is to evaluate whether the use of NT-proBNP testing and point-of-care ultrasound (POCUS) can improve the diagnosis and management of heart failure in adults aged 50 years or older with suspected heart failure or cardiovascular risk factors in primary care settings. The main questions it aims to answer are: * Does the use of NT-proBNP and/or POCUS increase the rate of new heart failure diagnoses compared with standard care? * Does this approach support earlier initiation of guideline-directed medical therapy and improve patients' quality of life? Researchers will compare standard care alone with standard care combined with NT-proBNP testing, POCUS, or both, to assess their impact on diagnosis and management of heart failure. Participants will: * Be randomly assigned to one of four groups (standard care, NT-proBNP, POCUS, or both). * Undergo clinical evaluation for heart failure according to their assigned group. * Be followed for 12 months with periodic assessments of quality of life and treatment adherence.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
160
Measurement of N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in blood as part of the diagnostic evaluation for suspected heart failure in primary care.
Cardiac point-of-care ultrasound performed by trained primary care physicians to assess cardiac structure and function as part of the diagnostic evaluation for suspected heart failure.
Usual clinical evaluation and management in primary care according to standard practice, without additional diagnostic interventions specified in the study.
Unidade de Saúde Familiar Conde da Lousã
Amadora, Portugal
NOT_YET_RECRUITINGUnidade de Saúde Familiar do Parque
Lisbon, Portugal
NOT_YET_RECRUITINGUnidade de Saúde Familiar Rodrigues Miguéis
Lisbon, Portugal
NOT_YET_RECRUITINGUnidade de Saúde Familiar Garcia Orta
Porto, Portugal
RECRUITINGNew Heart Failure Diagnosis
Proportion of participants with a new diagnosis of heart failure established during follow-up based on clinical evaluation and diagnostic testing according to routine practice.
Time frame: From baseline to 12 months
Initiation of Guideline-Directed Medical Therapy (GDMT)
Proportion of participants in whom guideline-directed medical therapy for heart failure is initiated during follow-up.
Time frame: From baseline to 12 months
Change in Health-Related Quality of Life (KCCQ-12)
Change from baseline in health-related quality of life as measured by the Kansas City Cardiomyopathy Questionnaire 12 (KCCQ-12) score.
Time frame: From baseline to 12 months
Cost-effectiveness of diagnostic strategies
Evaluation of the cost-effectiveness of diagnostic strategies incorporating NT-proBNP testing and/or point-of-care ultrasound (POCUS), including direct healthcare costs (e.g., diagnostic testing and referrals) and indirect costs (e.g., patient time and productivity loss).
Time frame: From baseline to 12 months
Quality of Cardiac POCUS Examinations
Assessment of the quality and interpretability of cardiac point-of-care ultrasound (POCUS) examinations performed by trained primary care physicians, based on expert review.
Time frame: From baseline to 12 months
Healthcare Resource Utilization
Assessment of healthcare resource utilization, including the number of conventional echocardiograms performed and referrals to specialist care.
Time frame: From baseline to 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.